Invitrogen last week said in an SEC filing that Ben Bulkley, its senior vice president of commercial operations, and John Radak, its finance and principal accounting officer, will leave the company at the end of January.
Bulkley will be replaced by Bernd Brust, Invitrogen’s general manager and vice president of European operations. Brust will be responsible for sales strategies, customer relations, and identifying avenues for customer growth, the company said.
Radak will be replaced by Kelli Richard, who has served as corporate controller at Invitrogen and as vice president and controller at Gateway.
David Wellis was appointed CEO of DNA sample storage company GenVault in mid-December, the company said last week.
Before coming to GenVault Wellis was vice president of functional genomics at Axon Instruments.